Introduction
Metabolic acidosis is defined as an excessive accumulation of non-volatile acid manifested as a primary reduction in serum bicarbonate concentration in the body associated with low plasma pH. Certain conditions may exist with other acid-base disorders such as metabolic alkalosis and respiratory acidosis/alkalosis 1 .
Humans possess homeostatic mechanisms that maintain acidbase balance (Figure 1 ). One utilizes both bicarbonate and nonbicarbonate buffers in both the intracellular and the extracellular milieu in the immediate defense against volatile (mainly CO 2 ) and non-volatile (organic and inorganic) acids before excretion by the lungs and kidneys, respectively. Renal excretion of non-volatile acid is the definitive solution after temporary buffering. This is an intricate and highly efficient homeostatic system. Derangements in over-production, under-excretion, or both can potentially lead to accumulation of excess acid resulting in metabolic acidosis (Figure 1 ).
Drug-induced metabolic acidosis is often mild, but in rare cases it can be severe or even fatal. Not only should physicians be keenly aware of this potential iatrogenic complication but they should also be fully engaged in understanding the pathophysiological mechanisms. Metabolic acidosis resulting from drugs and/or ingestion of toxic chemicals can be grouped into four general categories ( Figure 2 ):
1. Drugs as exogenous acid loads 2. Drugs leading to loss of bicarbonate in the gastrointestinal (GI) tract or kidney 3. Drugs causing increased endogenous acid production 4. Drugs that decrease renal acid excretion Some medications cannot be placed into one single category, as they possess multiple mechanisms that can cause metabolic acidosis.
In suspected drug-induced metabolic acidosis, clinicians should establish the biochemical diagnosis of metabolic acidosis along with the evaluation of respiratory compensation and whether there is presence of mixed acid-based disorders 2 , then convert the biochemical diagnosis into a clinical diagnosis with identification of the invading acid/drug 3 . Next is to review the list of medications by history and record to determine whether any of the drugs are culprits in either the generation or the exacerbation of the disorder. Note that just because a patient has, for example, lactic acidosis and is on a drug that can potentially cause lactic acidosis does not mean that the two are causally related. Finally, if a drug is indeed causing some degree of metabolic acidosis, the clinician should make an appraisal of the benefits from the drug weighed against the severity of the metabolic complication to determine whether cessation of therapy is justified. For example, if a patient with problematic seizures is effectively controlled by topiramate, a mild degree of metabolic acidosis can be more tolerable than seizures. are volatile alcohols that produce a high plasma osmolar gap (the alcohol itself and the aldehyde metabolite), pure high anion gap metabolic acidosis from their metabolism into strong carboxylic acids such as formic acid (from methanol), and a combination of oxalic, glyoxylic, and glycolic acid (from ethylene/diethylene glycol). Isopropanol alcohol, due to the absence of an alpha-carbon, could only be metabolized to a keto-group and contributes to an osmolar gap but not high anion gap metabolic acidosis in poisoning encounters. Toluene abuse with glue or paint thinner sniffing can cause hippuric metabolic acidosis that presents with a normal plasma anion gap but elevated urinary osmolar gap because of the rapid clearance of hippurate 8 . Note that the time at which blood is sampled may reveal variable osmolar and anion gap. When the hydroxyl group is metabolized to carboxyl with a low pKa, there will not be an osmolar gap due to the contemporaneous consumption of bicarbonate; however, the metabolite between hydroxyl and carboxyl is an aldehyde, which still contributes to an osmolar gap but not an anion gap.
Drugs resulting in exogenous acid precursors
Ammonium chloride is not usually abused but is used extensively by investigators to study overproduction acidosis and used outside the laboratory 9 . There is a rise in acid excretion and a fall in serum HCO 3 -concentration that remains constant after initial drop 10, 11 .
Overproduction acidosis from pharmaceutical agents
The excessive use of amino acids with a net positive charge would result in liberation of H + during metabolism (arginine and lysine) in parenteral alimentation with inadequate concomitant administration of alkali 12 . Another example in this category is propylene glycol (1,2-propanediol [PG]), a common hygroscopic and emulsifying agent that is metabolized to lactate 13 . The U.S. Food and Drug Administration classified PG as GRAS (generally recognized as safe). The recommended maximum daily intake of PG should be less than 25 mg/kg/day (equivalent to 21 mmol/day for a 70 kg person) 14 . Each drug injection may have very different amounts of PG. Clinically significant toxicity is seen only in rapid, massive, and protracted parenteral administration of high quantities, especially in patients with renal impairment. PG intoxication from intravenous vitamin therapy was reported in pediatric patients who developed stupor 15 . Intoxication with lactic acidosis and hyperosmolality were found during treatment of schizophrenia 16 , with the use of intravenous benzodiazepines 13, 17 , etomidate 18 , nitroglycerin 19 , and barbiturates 20 , all with PG as a vehicle. Approximately 55% of PG undergoes oxidation to propionaldehyde and pyruvic, acetic, and lactic acid, while the remainder is excreted unchanged in the urine 21, 22 . Some studies have demonstrated PG-injured proximal tubular cells, leading to impaired renal acidification 20, 23 . Patients with hepatic dysfunction, renal insufficiency, and diabetic ketoacidosis are more susceptible to PG toxicity and development of lactic acidosis 24 . The sulfonamide class of drugs also has CA inhibitory activity. Topical application and absorption over large areas in burn patients can cause extremely high blood levels and systemic CA inhibition 36 . This results in more than mere renal bicarbonate loss but rather a systemic disequilibrium syndrome.
Drugs causing external base loss

Gastrointestinal loss of bicarbonate
Cholestyramine is an oral agent for treating hypertriglyceridemia and cholestasis by binding and sequestering bile acids from the entero-hepatic circulation; the non-absorbable complexes are eventually excreted in the stool 37 . In the GI tract, cholestyramine also binds phosphate, sulfate, and bicarbonate, leading to potential loss of bicarbonate from the body. Under normal conditions, this is easily corrected by renal regeneration of bicarbonate. However, patients with impaired renal function are at risk of hyperchloremic acidosis [37] [38] [39] .
Sevelamer hydrochloride is a non-reabsorbable phosphate binder. Dialysis patients on sevelamer hydrochloride have lower mean serum bicarbonate concentration during and at the end of therapy compared to those treated with calcium acetate 40, 41 . Figure 3 .
Most cases of MALA were associated with some underlying conditions such as acute renal failure induced by volume depletion, other potential nephrotoxic agents and concurrent use of radio-contrast media, or hepatic insufficiency [54] [55] [56] [57] [58] . Blood pH and lactate levels are not prognostic in MALA
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. Although the incidence of MALA is low, once developed, the mortality can be staggeringly high 52 , particularly in the critical care setting, so discontinuation is advised in a patient with impending renal and multi-organ failure. Recently, a less restrictive guideline is proposed on metformin usage in patients of stable chronic kidney disease [60] [61] [62] [63] . In general, the mortality of MALA decreased from 50% to 25% from the 1960s to the present 64 .
Highly active antiretroviral therapy (HAART) has led to dramatic reductions in HIV-associated morbidity and mortality 65 ( Figure 3 ). However, lactic acidosis complicated this therapy, especially with the nucleoside and nucleotide reverse transcriptase inhibitor (NRTI)-based regimens: didanosine, stavudine, lamivudine, zidovudine, and abacavir [66] [67] [68] [69] [70] [71] . Combined use of these drugs further increases the risk of lactic acidosis 72 . Moreover, didanosine 73 , cidofovir 74 , lamivudine, and stavudine 75 could cause Fanconi syndrome with pan-proximal tubular dysfunction leading to exacerbation of the acidosis and reduction of the plasma anion gap. The mortality of HAART-induced lactic acidosis can be as high as 50% 76 .
Linezolid is a long-term antibiotic against serious resistant Grampositive organisms 77,78 with adverse effects including bone marrow toxicity, optic/peripheral neuropathy, and lactic acidosis 77, 79, 80 . Concurrent use of selective serotonin uptake inhibitors such as citalopram and sertraline may predispose patients to lactic acidosis 81, 82 . The vast majority of lactic acidosis occurred in the elderly and those receiving prolonged treatment, and most resolved upon cessation of linezolid 80 . Children receiving linezolid appeared to suffer lactic acidosis earlier during treatment 83 ( Figure 3 ).
Isoniazid is commonly used to treat tuberculosis 84 . Dosing more than 300 mg/day can lead to refractory grand mal or localized seizure, coma, and lactic acidosis [84] [85] [86] . Some suggested acidosis stems from excessive muscle activity during refractory seizure 86, 87 , and slow reversal was observed in the postictal period. One proposed mechanism is inhibition of conversion of lactate to pyruvate 84, [87] [88] [89] ( Figure 3 ).
Propofol is commonly used for induction and maintenance of anesthesia, sedation, and interventional procedures. Two cases were reported on propofol-associated severe metabolic acidosis 90, 91 . Risk factors include severe head injury, critical illness, prolonged administration (>48 hours) of large doses (>4 mg/kg/hour, equivalent to 1.6 mmol/hour for a 70 kg person), and inborn errors of fatty acid oxidation 90,92 ( Figure 3 ).
Ketoacidosis
Ketosis develops when metabolism of fatty acid exceeds the removal of ketoacids (acetoacetic and β-hydroxybutyric). Typically there is insulin deficiency and/or resistance coupled with elevated glucagon and catecholamine. Glucose utilization is impaired and lipolysis is increased, augmenting the delivery of glycerol, alanine, and fatty acids for ketoacid generation 45, 93 .
Overdose with salicylates in children commonly produces high anion gap acidosis, while adults exhibit a mixed respiratory alkalosis and metabolic acidosis. Metabolic acidosis occurs during salicylate toxicity due to uncoupling of oxidative phosphorylation and interfering with the Krebs cycle 45, 86 , resulting in accumulation of lactic acid and ketoacids in as many as 40% of adult patients with salicylate poisoning 45, 94, 95 . The anion gap is mainly composed of ketoanions and lactate, while salicylate anion seldom exceeds 3 mEq/L.
Alcoholic ketoacidosis occurs when ethanol is abused chronically in the setting of poor carbohydrate intake and volume contraction. Ketosis resolves when the ethanol intake is interrupted and the patient is provided with nutrients and fluid, which stimulates insulin secretion and promotes the regeneration of bicarbonate from the metabolism of ketoacid anions 45 .
Pyroglutamic acidosis
The γ-glutamyl cycle produces glutathione, which is involved in the inactivation of free radicals, detoxification of many compounds, and amino acid transport 45, 96, 97 . Acetaminophen can deplete glutathione, leading to increased formation of γ-glutamyl cysteine, which is converted and accumulated as pyroglutamic acid (5-oxoproline) 45, 97 . Patients at risk include those with malnutrition, sepsis, alcohol abuse, underlying liver disease, and/or renal insufficiency 96 . Acetaminophen ingestion alone may not cause pyroglutamic acidosis, but synergistic interaction between acetaminophen and the other factors as noted above 96 can. Concomitant use of other drugs such as aminoglycoside and β-lactam penicillin is reported to increase the risk 98 . . Hyperkalemia suppresses ammoniagenesis in the proximal tubule, impairs NH 4 + transport in the medullary thick ascending limb, and reduces medullary interstitial ammonium concentration, all of which can lower urine acid excretion 45, 102 . Therefore, any drug that affects the RAAS or causes hyperkalemia can increase the risk of metabolic acidosis. These drugs include the following (Figure 4 114, 115 When these drugs are administered in combination, there is increased risk for hyperkalemia and metabolic acidosis, especially in patients with diabetes, chronic kidney disease, and liver disease 45 .
Drugs causing decreased renal acid excretion
In contrast, patients with classic distal renal tubular acidosis (dRTA) generally have hypokalemic hyperchloremic metabolic acidosis. The metabolic acidosis results from the inability to acidify urine in the distal nephron and impaired excretion of NH4 +100 . 3 -is delivered to the distal tubule, which has limited capacity for HCO 3 -reabsorption. Bicarbonaturia ensues and net acid excretion decreases, which eventually leads to metabolic acidosis 45, 120 . Generalized proximal tubule dysfunction is termed Fanconi syndrome. Potential drugs that could induce Fanconi syndrome include the following ( Figure 5 ): -CA inhibitors (e.g. acetazolamide)
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-Anti-viral/HIV drugs (e.g. lamivudine, stavudine 75 and tenofovir [121] [122] [123] [124] ). Most tenofovir-induced cases are subclinical 125 -Platinum-containing agents (e.g. cisplatin 126, 127 ) and DNA alkylating agents (e.g. ifosfamide [128] [129] [130] ) are common proximal have also been associated with Fanconi syndrome in case reports. This field remained to be further explored as proximal tubule toxicity is common due to the existence of multiple drug transporters at the surface membrane, leading to very high uptake of drugs by this segment 147 .
Conclusion
In summary, metabolic acidosis can occur as a side effect of therapy. Instead of memorizing the catalogue of drugs, clinicians should classify these agents based on their pathophysiologic mechanisms to facilitate the recognition of potential causal relationships. Some of these side effects are inferred from empirical observations, but some have undergone extensive studies to determine the pathogenesis of metabolic acidosis. We hope that this review will intrigue our readers to experience that eureka moment identifying unrecognized explanations for metabolic acidosis in patients or to partake in extending clinical observations to clinical investigations.
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